Revolution Medicines
RVMD
130 hedge funds and large institutions have $2.23B invested in Revolution Medicines in 2021 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 64 increasing their positions, 19 reducing their positions, and 18 closing their positions.
237% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 19
16% more call options, than puts
Call options by funds: $1.51M | Put options by funds: $1.3M
11% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 18
5.25% more ownership
Funds ownership: 90.57% → 95.81% (+5.2%)
2% more funds holding
Funds holding: 128 → 130 (+2)
20% less funds holding in top 10
Funds holding in top 10: 10 → 8 (-2)
27% less capital invested
Capital invested by funds: $3.05B → $2.23B (-$816M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$57.9M |
| 2 |
BlackRock
New York
|
+$34.5M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$31.1M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$28.4M |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$27.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGI
TRV GP II
Boston,
Massachusetts
|
-$87.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$45.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$32.1M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$26.1M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
-$16M |
RVMD Hedge Fund Activity: Q2 2021 in Review
130 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Revolution Medicines (RVMD) for Q2 2021, worth a combined $2.23B — down 27% from $3.05B a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new RVMD positions and 18 closed out — a net gain of 2 holders — while 64 added to existing stakes and 19 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $57.9M. The largest seller was TRV GP II, exiting entirely with an estimated $87.6M sold.
- 130 institutional investors held Revolution Medicines (RVMD) as of Q2 2021, up from 128 in Q1 2021.
- Funds reported $2.23B of Revolution Medicines stock for Q2 2021, down 27% quarter-over-quarter.
- 20 funds opened new Revolution Medicines positions in Q2 2021 and 18 closed out, a net change of +2 holders.
- The largest Revolution Medicines buyer in Q2 2021 was Wellington Management Group, an estimated $57.9M added.
- The largest Revolution Medicines seller in Q2 2021 was TRV GP II, an estimated $87.6M sold.
Based on aggregated 13F filings for Q2 2021.